

Supplementary Figure 1: $\alpha 4\beta 7$ -expression on and vedolizumab binding to different leukocyte subsets

(A,B) Representative (A) and quantitative (B) flow cytometry of $\alpha 4^+\beta 7^+$ cells within CD4+, CD3+CD8+, CD3-CD19+, CD3-CD56+CD16+ NK cells, CD3-CD16+CD14+ monocytes, CD16+ neutrophils and CD16-CCR3+Siglec8+ eosinophils (left panel) and quantification of $\alpha 4^+\beta 7^+$ VDZ- cells after incubation with 10 μ g/ml VDZ. n = 6-53 IBD patients or healthy controls per group as indicated.

Statistical comparisons were performed using One-Way-Anova with Tukey's multiple comparisons post-hoc test

(C) Representative flow cytometry of controls for $\alpha 4^+$ and $\beta 7^+$ cells in the different leukocyte subsets shown in A and B.

Sample donor characteristics are listed in Supplementary Table S12.